X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 33.6 20.2 166.5% View Chart
P/BV x 5.3 4.0 133.4% View Chart
Dividend Yield % 0.6 0.3 204.1%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
AUROBINDO PHARMA
Mar-18
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365809 292.3%   
Low Rs1,625504 322.4%   
Sales per share (Unadj.) Rs430.3281.1 153.1%  
Earnings per share (Unadj.) Rs78.741.4 190.3%  
Cash flow per share (Unadj.) Rs93.250.9 183.2%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %1.00.4 263.3%  
Book value per share (Unadj.) Rs586.5199.4 294.2%  
Shares outstanding (eoy) m45.75585.88 7.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.3 198.5%   
Avg P/E ratio x25.315.9 159.7%  
P/CF ratio (eoy) x21.412.9 165.9%  
Price / Book Value ratio x3.43.3 103.3%  
Dividend payout %25.46.0 420.4%   
Avg Mkt Cap Rs m91,271384,630 23.7%   
No. of employees `0002.617.3 15.2%   
Total wages/salary Rs m3,14321,308 14.7%   
Avg. sales/employee Rs Th7,484.89,500.7 78.8%   
Avg. wages/employee Rs Th1,195.01,229.4 97.2%   
Avg. net profit/employee Rs Th1,369.11,397.9 97.9%   
INCOME DATA
Net Sales Rs m19,685164,666 12.0%  
Other income Rs m1,1431,020 112.1%   
Total revenues Rs m20,828165,686 12.6%   
Gross profit Rs m5,00337,718 13.3%  
Depreciation Rs m6635,580 11.9%   
Interest Rs m4777 0.5%   
Profit before tax Rs m5,47932,380 16.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8788,183 23.0%   
Profit after tax Rs m3,60124,229 14.9%  
Gross profit margin %25.422.9 111.0%  
Effective tax rate %34.325.3 135.7%   
Net profit margin %18.314.7 124.3%  
BALANCE SHEET DATA
Current assets Rs m24,167121,878 19.8%   
Current liabilities Rs m9,54486,806 11.0%   
Net working cap to sales %74.321.3 348.8%  
Current ratio x2.51.4 180.3%  
Inventory Days Days55130 42.4%  
Debtors Days Days2968 42.0%  
Net fixed assets Rs m9,51481,037 11.7%   
Share capital Rs m458586 78.1%   
"Free" reserves Rs m26,375116,218 22.7%   
Net worth Rs m26,832116,804 23.0%   
Long term debt Rs m254,512 0.6%   
Total assets Rs m36,900211,052 17.5%  
Interest coverage x1,305.542.7 3,060.1%   
Debt to equity ratio x00 2.4%  
Sales to assets ratio x0.50.8 68.4%   
Return on assets %9.811.8 82.5%  
Return on equity %13.420.7 64.7%  
Return on capital %20.427.4 74.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2280,727 0.0%   
Fx outflow Rs m1,48934,700 4.3%   
Net fx Rs m-1,46646,027 -3.2%   
CASH FLOW
From Operations Rs m3,31819,548 17.0%  
From Investments Rs m-2,383-19,570 12.2%  
From Financial Activity Rs m-1,1048,642 -12.8%  
Net Cashflow Rs m-1698,922 -1.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 324 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Apr 25, 2019 (Close)

TRACK PFIZER

PFIZER - CADILA HEALTHCARE COMPARISON

COMPARE PFIZER WITH

MARKET STATS